Education
About Us
Working with TipRanks
Follow Us
Valerio Therapeutics (FR:ALVIO)
:ALVIO
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.04 - €0.31
Previous CloseN/A
Volume8.86K
Average Volume (3M)1.36M
Market Cap
€73.54M
Enterprise Value€67.51M
Total Cash (Recent Filing)€2.64M
Total Debt (Recent Filing)€18.57M
Price to Earnings (P/E)―
Beta-1.40
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume527,429
30 Day Avg. Volume1,357,798
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-1.29
Price to Sales (P/S)6.44
P/FCF Ratio-0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Profit MarginA strong gross profit margin indicates efficient production and pricing strategies, providing a buffer against operational challenges and potential cost increases.
Research And Development FocusThe focus on R&D for cancer therapies positions the company to address significant unmet medical needs, potentially leading to breakthrough products and long-term growth.
Revenue StreamsDiverse revenue streams from product sales, royalties, and partnerships enhance financial resilience and provide multiple avenues for growth as the pipeline matures.
Bears Say
Declining RevenueA declining revenue trend can hinder the company's ability to invest in R&D and other growth initiatives, potentially impacting long-term competitiveness and market position.
Negative Cash FlowNegative cash flow indicates potential liquidity issues, limiting the company's ability to fund operations and strategic initiatives without external financing.
Financial InstabilityHigh leverage and negative equity suggest financial instability, increasing the risk of financial distress and limiting the company's ability to withstand economic downturns.
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.31 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €73.54M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Technical Analysis
Hybrigenics SA Class A
―
TME Pharma N.V.
―
Biophytis SA
―
Theranexus SA
―
NFL Biosciences SA
―